Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO-TAG: Tagraxofusp-erzs and Gemtuzumab Ozogamicin in Relapsed/Refractory AML
NCT05716009Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of tagraxofusp in acute myeloid leukemia (AML) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Recommended Phase 2 Dose at 2.5 years and Safety and Tolerability at 2.5 years. Started Nov 2023; status: terminated.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05716009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716009.